KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Capital Expenditures (2016 - 2025)

Neogenomics (NEO) has disclosed Capital Expenditures for 16 consecutive years, with -$17.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 144.25% year-over-year to -$17.4 million, compared with a TTM value of $1.7 million through Dec 2025, down 95.83%, and an annual FY2025 reading of $1.7 million, down 95.83% over the prior year.
  • Capital Expenditures was -$17.4 million for Q4 2025 at Neogenomics, down from $8.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $62.0 million in Q4 2021 and bottomed at -$35.0 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $6.9 million, with a median of $1.6 million recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 5358.32% in 2021, while the deepest fall reached 331.69% in 2021.
  • Year by year, Capital Expenditures stood at $62.0 million in 2021, then plummeted by 99.12% to $544000.0 in 2022, then surged by 5068.38% to $28.1 million in 2023, then soared by 40.04% to $39.4 million in 2024, then plummeted by 144.25% to -$17.4 million in 2025.
  • Business Quant data shows Capital Expenditures for NEO at -$17.4 million in Q4 2025, $8.3 million in Q3 2025, and $6.3 million in Q2 2025.